Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era.
作者信息
Gandini Lucia, Fior Gabriele, Schibler Andreas, Obonyo Nchafatso G, Li Bassi Gianluigi, Suen Jacky Y, Fraser John F
机构信息
Critical Care Research Group, The Prince Charles Hospital, University of Queensland, Brisbane, QLD, Australia.
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
出版信息
Crit Care. 2023 Mar 25;27(1):124. doi: 10.1186/s13054-023-04394-w.
Abstract
摘要
相似文献
1
Interleukin-6 inhibitors in non-COVID-19 ARDS: analyzing the past to step into the post-COVID-19 era.非新冠病毒感染的急性呼吸窘迫综合征中的白细胞介素-6抑制剂：回顾过去，迈入新冠后时代
Crit Care. 2023 Mar 25;27(1):124. doi: 10.1186/s13054-023-04394-w.
2
Can acute respiratory distress syndrome be treated?急性呼吸窘迫综合征能被治愈吗？
Future Med Chem. 2021 Apr;13(8):687-690. doi: 10.4155/fmc-2021-0014. Epub 2021 Mar 16.
3
Corticosteroids in adult respiratory distress syndrome - an inconvenient truth?成人呼吸窘迫综合征中的皮质类固醇——一个令人尴尬的事实？
Int J Pharm Pract. 2021 Dec 4;29(6):642-644. doi: 10.1093/ijpp/riab053.
4
Repurposing Multiple-Molecule Drugs for COVID-19-Associated Acute Respiratory Distress Syndrome and Non-Viral Acute Respiratory Distress Syndrome via a Systems Biology Approach and a DNN-DTI Model Based on Five Drug Design Specifications.通过系统生物学方法和基于五个药物设计规范的 DNN-DTI 模型，重新利用多种分子药物治疗 COVID-19 相关急性呼吸窘迫综合征和非病毒性急性呼吸窘迫综合征。
Int J Mol Sci. 2022 Mar 26;23(7):3649. doi: 10.3390/ijms23073649.
5
Salvage use of tissue plasminogen activator (tPA) in the setting of acute respiratory distress syndrome (ARDS) due to COVID-19 in the USA: a Markov decision analysis.美国 COVID-19 导致的急性呼吸窘迫综合征（ARDS）中组织型纤溶酶原激活剂（tPA）的补救性应用：一项马尔可夫决策分析。
World J Emerg Surg. 2020 Apr 20;15(1):29. doi: 10.1186/s13017-020-00305-4.
6
Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS).氨苯砜、秋水仙碱和奥氮平作为辅助治疗药物预防新型冠状病毒肺炎相关的成人呼吸窘迫综合征（ARDS）。
Med Hypotheses. 2020 Aug;141:109774. doi: 10.1016/j.mehy.2020.109774. Epub 2020 Apr 23.
7
COVID-19 and non-COVID ARDS patients demonstrate a distinct response to low dose steroids- A retrospective observational study.COVID-19 和非 COVID-19 导致的急性呼吸窘迫综合征患者对低剂量类固醇的反应明显不同——一项回顾性观察研究。
J Crit Care. 2021 Apr;62:46-48. doi: 10.1016/j.jcrc.2020.11.012. Epub 2020 Nov 21.
8
Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile?吸入一氧化氮治疗 COVID-19 诱导的 ARDS 的效果如何——是否值得？
Acta Anaesthesiol Scand. 2021 May;65(5):629-632. doi: 10.1111/aas.13757. Epub 2020 Dec 20.
9
Latent Class Analysis Reveals COVID-19-related Acute Respiratory Distress Syndrome Subgroups with Differential Responses to Corticosteroids.潜类分析揭示 COVID-19 相关急性呼吸窘迫综合征亚组对皮质类固醇的反应存在差异。
Am J Respir Crit Care Med. 2021 Dec 1;204(11):1274-1285. doi: 10.1164/rccm.202105-1302OC.
10
Sedation Usage in COVID-19 Acute Respiratory Distress Syndrome: A Multicenter Study.COVID-19 急性呼吸窘迫综合征中的镇静使用：一项多中心研究。
Ann Pharmacother. 2022 Feb;56(2):117-123. doi: 10.1177/10600280211021925. Epub 2021 Jun 2.
引用本文的文献
1
Hypoxic Status in COPD and ARDS Patients: Impact on Lipid Signature.慢性阻塞性肺疾病（COPD）和急性呼吸窘迫综合征（ARDS）患者的缺氧状态：对脂质特征的影响。
Int J Mol Sci. 2025 Jul 3;26(13):6405. doi: 10.3390/ijms26136405.
2
Prone Positioning and Molecular Biomarkers in COVID and Non-COVID ARDS: A Narrative Review.俯卧位通气与新冠及非新冠急性呼吸窘迫综合征中的分子生物标志物：一项叙述性综述
J Clin Med. 2024 Jan 5;13(2):317. doi: 10.3390/jcm13020317.
3
Administration of tocilizumab in septic patients with pancytopenia and hyper-inflammatory syndrome.在患有全血细胞减少症和高炎症综合征的脓毒症患者中使用托珠单抗。
Ann Hematol. 2023 Sep;102(9):2633-2634. doi: 10.1007/s00277-023-05335-x. Epub 2023 Jun 26.
本文引用的文献
1
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.COVID-19 住院患者中使用白细胞介素 6 拮抗剂与死亡率的关系：一项荟萃分析。
JAMA. 2021 Aug 10;326(6):499-518. doi: 10.1001/jama.2021.11330.
2
Antiinflammatory effects of adalimumab, tocilizumab, and steroid on lipopolysaccharide-induced lung injury.阿达木单抗、托珠单抗和类固醇对脂多糖诱导的肺损伤的抗炎作用。
Turk J Med Sci. 2021 Oct;51(5):2741-2751. doi: 10.3906/sag-2010-303. Epub 2021 Oct 21.
3
Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome.抗白细胞介素-6受体单克隆抗体在药物性急性呼吸窘迫综合征中的应用
Case Rep Crit Care. 2020 Jul 22;2020:8832986. doi: 10.1155/2020/8832986. eCollection 2020.
4
ARDS Subphenotypes: Understanding a Heterogeneous Syndrome.急性呼吸窘迫综合征（ARDS）亚表型：理解一种异质性综合征。
Crit Care. 2020 Mar 24;24(1):102. doi: 10.1186/s13054-020-2778-x.
5
Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein.托珠单抗通过下调 NF-κB/JNK 减轻脓毒症大鼠的急性肺和肾损伤并提高存活率：P-糖蛋白的可能作用。
Inflammopharmacology. 2020 Feb;28(1):215-230. doi: 10.1007/s10787-019-00628-y. Epub 2019 Aug 22.
6
Interleukin-6: designing specific therapeutics for a complex cytokine.白细胞介素 6：为复杂细胞因子设计特异性治疗药物。
Nat Rev Drug Discov. 2018 Jun;17(6):395-412. doi: 10.1038/nrd.2018.45. Epub 2018 May 4.
7
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.美国食品和药物管理局批准概要：托西珠单抗治疗嵌合抗原受体 T 细胞引起的严重或危及生命的细胞因子释放综合征。
Oncologist. 2018 Aug;23(8):943-947. doi: 10.1634/theoncologist.2018-0028. Epub 2018 Apr 5.
8
Effects of Tocilizumab on Experimental Severe Acute Pancreatitis and Associated Acute Lung Injury.托珠单抗对实验性重症急性胰腺炎及其相关急性肺损伤的影响。
Crit Care Med. 2016 Aug;44(8):e664-77. doi: 10.1097/CCM.0000000000001639.
9
IL-6 cytoprotection in hyperoxic acute lung injury occurs via PI3K/Akt-mediated Bax phosphorylation.白细胞介素-6在高氧性急性肺损伤中的细胞保护作用通过磷脂酰肌醇-3激酶/蛋白激酶B介导的 Bax 磷酸化实现。
Am J Physiol Lung Cell Mol Physiol. 2009 Jul;297(1):L6-16. doi: 10.1152/ajplung.90381.2008. Epub 2009 Apr 17.
Zotero 插件